联合治疗合并过敏性鼻炎的支气管哮喘患者的临床分析

目的 观察糠酸莫米松鼻喷剂联合沙美特罗/丙酸氟替卡松干粉吸入剂对合并过敏性鼻炎的支气管哮喘患者的治疗效果.方法 56例合并过敏性鼻炎的支气管哮喘患者,随机分为两组,对照组28例,给予吸入沙美特罗/丙酸氟替卡松 50/250 μg,1吸/次,2次/d.试验组28例,在吸入美特罗/丙酸氟替卡松治疗基础上,同时给予糠酸莫米松鼻喷剂治疗,每个鼻孔各1喷,50 μg/喷,2次/d,治疗时间为3个月.分别于治疗前后观察哮喘控制测试（ACT）评分、用力肺活量（FVC）、第一秒呼气容积（FEV1）,比较不同治疗方法的疗效.结果 试验组比对照组能显著提高ACT评分,患者的FVC、FEV1亦有明显改善,差异有统计学意义（ P 〈0.05）.结论 联合治疗过敏性鼻炎和支气管哮喘比单纯治疗支气管哮喘能显著提高支气管哮喘患者的治疗效果,有效地提高患者的生存质量.

The clinical analysis of combined treatment on allergic rhinitis and asthma

Objective To evaluate the therapeutic effect of mometasone furoate monohydrate nasal spray in combination with inhaled - powder salmeterol/fluticasone in treating allergic rhinitis and asthma syndrome. Methods 56 cases were divided into two groups randomly. The control group was treated with salmeterol/fluticasone 50/250μg twice daily. On the basis of inhalation ,the treatment group was added mometasone furoate monohydrate nasal spray 50p.g into each nostril twice daily, for 3 months. The forced expiratory volume in one second （FEV1 ）, the forced vital capacity （FVC） and asthma control test（ACT） were observed respectively. Results The treatment group was significantly higher than the control group on the score of ACT, FEVI and FVC, there were significant differences （ P 〈 0.05 ）. Conclusion On the basis of inhaled salmeterel/ fluticascne, added mometasone fureate monohydrate nasal spray to the patients with combined allergic rhinitis and asthma can improve the efficacy of the treatment to asthma.